Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

TRAIL receptor-targeted therapy.

Donald J Buchsbaum¹, Tong Zhou, Albert F Lobuglio

¹University of Alabama at Birmingham, Comprehensive Cancer Center, Department of Radiation Oncology, 1824 6th Avenue South, WTI 674, Birmingham, AL 35294-6832, USA. djb@uab.edu

Future Oncology (London, England)

|August 23, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Cancers·2026

Same author

Jump-starting the T cell response in established tumors.

bioRxiv : the preprint server for biology·2026

Same author

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma.

bioRxiv : the preprint server for biology·2026

Same author

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.

Cancers·2025

Same author

Editorial: RAS inhibitor therapy of cancer.

Frontiers in oncology·2025

Same author

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.

Molecular cancer·2025

Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026

Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026

Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026

Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026

Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026

Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026

See all related articles

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) shows promise in cancer therapy by selectively inducing cancer cell death. TRAIL, alone or combined with chemotherapy or radiation, is being investigated in clinical trials for targeted cancer treatment.

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a cytokine that induces apoptosis in cancer cells.
TRAIL is being developed as a biological agent for cancer therapy due to its selective cytotoxicity.
Chemotherapy and radiotherapy can enhance TRAIL's anticancer effects.

Purpose of the Study:

To review TRAIL receptor-mediated apoptosis in tumor cells.
To discuss the use of TRAIL or agonistic monoclonal antibodies, alone or with chemotherapy, for cancer therapy.
To present preclinical and early clinical trial data on TRAIL-based therapies.

Main Methods:

Review of preclinical studies on TRAIL receptor-mediated apoptosis.
Analysis of studies combining TRAIL ligands with chemotherapy or radiotherapy.

Related Experiment Videos

Examination of preliminary clinical trial data for TRAIL receptor ligands.

Main Results:

TRAIL selectively induces apoptosis in various cancer cell lines and tumor xenografts.
Combination therapies of TRAIL with chemotherapy or radiation show enhanced cytotoxic effects.
Preclinical data support the use of agonistic monoclonal antibodies targeting TRAIL death receptors.

Conclusions:

TRAIL and its receptor ligands show potential for targeted cancer therapy.
Combination regimens involving TRAIL receptor ligands require further clinical trials.
Additional research is needed to establish the efficacy of TRAIL-based treatments in clinical settings.